NCT02867592 2026-04-13
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Bristol-Myers Squibb
Exelixis
Fundacion Clinic per a la Recerca Biomédica
Exelixis
Exelixis